logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Infinity Pharmaceuticals, Inc.


USPTO Granted Patents = 108

% Expired Patents = 41.7



Trademarks = 6

Forward Citations = 1,493

Loading Chart...
Loading Chart...

78 inventors (with patents filed for the assignee):

goldMedal Alfredo C Castro (63 out of 114 patents)

silverMedal Martin R Tremblay (38 out of 47 patents)

bronzeMedal Catherine Anne Evans (37 out of 44 patents)

4.  Michael J Grogan (33 out of 44 patents)

5.  Louis Grenier (32 out of 51 patents)

6.  Tao Liu (29 out of 38 patents)

7.  Daniel A Snyder (29 out of 34 patents)

8.  Andre Lescarbeau (28 out of 32 patents)

9.  Somarajannair Janardanannair (23 out of 24 patents)

10.  Pingda Ren (20 out of 139 patents)

11.  Julian Adams (20 out of 42 patents)

12.  Brian C Austad (18 out of 32 patents)

13.  James R Porter (18 out of 24 patents)

14.  Thomas T Tibbitts (17 out of 22 patents)

15.  Mark L Behnke (16 out of 28 patents)


Core Competencies:
Heterocyclic Compounds
PI3 Kinase Inhibitors
Cyclopamine Analogs
Isoquinolinones
Fatty Acid Amide Hydrolase
Combination Therapies
Enzymatic Transamination
Transfer Hydrogenation
Trisubstituted Bicyclic
Chemical Compounds
Kinase Modulation
Tetrazolones

108 patents:

1. 12213983 - Treatment of cancers using PI3 kinase isoform modulators (2025-02-04),
2. 12152032 - Heterocyclic compounds and uses thereof (2024-11-26),
3. 11944631 - Combination therapies (2024-04-02),
4. 11939333 - Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same (2024-03-26),
5. 11602527 - Methods of use of cyclopamine analogs (2023-03-14),
6. 11541059 - Heterocyclic compounds and uses thereof (2023-01-03),
7. 11312718 - Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (2022-04-26),
8. 11247995 - Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same (2022-02-15),
9. 11147818 - Combination therapies (2021-10-19),
10. 11110096 - Combination therapies (2021-09-07),
11. 11007181 - Cyclopamine analogs (2021-05-18),
12. 10941162 - Heterocyclic compounds and uses thereof (2021-03-09),
13. 10919914 - Heterocyclic compounds and uses thereof (2021-02-16),
14. 10821102 - Methods of use of cyclopamine analogs (2020-11-03),
15. 10759806 - Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors (2020-09-01),
Company Overview
Infinity Pharmaceuticals, Inc., based in Cambridge, MA, specializes in the development of innovative therapeutics focusing on heterocyclic compounds. The company is engaged in advancing treatments through its expertise in PI3 kinase inhibitors and cyclopamine analogs, among other core technologies. Infinity's research encompasses various areas, including isoquinolinones and fatty acid amide hydrolase, with a commitment to exploring combination therapies and enzymatic processes to enhance therapeutic efficacy.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Infinity Pharmaceuticals, Inc. USPTO Patent Assignee Logo
108 Patents

#26 in Cambridge, MA

#193 in Massachusetts

#3,542 in US

#7,287 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Infinity Pharmaceuticals, Inc.

Forward Citations = 1,493

78 inventors:

goldMedal Alfredo C Castro (63 out of 114 patents)

silverMedal Martin R Tremblay (38 out of 47 patents)

bronzeMedal Catherine Anne Evans (37 out of 44 patents)

4.  Michael J Grogan (33 out of 44 patents)

5.  Louis Grenier (32 out of 51 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Infinity Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/infinity-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…